JP2014527404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527404A5 JP2014527404A5 JP2014519553A JP2014519553A JP2014527404A5 JP 2014527404 A5 JP2014527404 A5 JP 2014527404A5 JP 2014519553 A JP2014519553 A JP 2014519553A JP 2014519553 A JP2014519553 A JP 2014519553A JP 2014527404 A5 JP2014527404 A5 JP 2014527404A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- vector
- residue
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims 51
- 229920001184 polypeptide Polymers 0.000 claims 48
- 239000013598 vector Substances 0.000 claims 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- 102000037865 fusion proteins Human genes 0.000 claims 26
- 108020001507 fusion proteins Proteins 0.000 claims 26
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 11
- 230000037430 deletion Effects 0.000 claims 9
- 238000012217 deletion Methods 0.000 claims 9
- 102100034343 Integrase Human genes 0.000 claims 8
- 101710203526 Integrase Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 6
- 238000007920 subcutaneous administration Methods 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 108700024845 Hepatitis B virus P Proteins 0.000 claims 3
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 208000007089 vaccinia Diseases 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000037452 priming Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000178270 Canarypox virus Species 0.000 claims 1
- 241001217856 Chimpanzee adenovirus Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000725618 Duck hepatitis B virus Species 0.000 claims 1
- 241000700662 Fowlpox virus Species 0.000 claims 1
- 241000598171 Human adenovirus sp. Species 0.000 claims 1
- 241000714192 Human spumaretrovirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 101710086987 X protein Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305909 | 2011-07-12 | ||
| EP11305909.1 | 2011-07-12 | ||
| EP12305450 | 2012-04-18 | ||
| EP12305450.4 | 2012-04-18 | ||
| PCT/EP2012/063640 WO2013007772A1 (en) | 2011-07-12 | 2012-07-12 | Hbv polymerase mutants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527404A JP2014527404A (ja) | 2014-10-16 |
| JP2014527404A5 true JP2014527404A5 (OSRAM) | 2015-08-27 |
| JP6189293B2 JP6189293B2 (ja) | 2017-08-30 |
Family
ID=46506427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519553A Expired - Fee Related JP6189293B2 (ja) | 2011-07-12 | 2012-07-12 | Hbvポリメラーゼ変異体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9512412B2 (OSRAM) |
| EP (1) | EP2732034B1 (OSRAM) |
| JP (1) | JP6189293B2 (OSRAM) |
| KR (1) | KR102061357B1 (OSRAM) |
| CN (1) | CN103998604B (OSRAM) |
| AU (1) | AU2012282506C1 (OSRAM) |
| BR (1) | BR112014000627B1 (OSRAM) |
| CA (1) | CA2841890C (OSRAM) |
| DK (1) | DK2732034T3 (OSRAM) |
| ES (1) | ES2632497T3 (OSRAM) |
| HU (1) | HUE033789T2 (OSRAM) |
| IL (1) | IL230402B (OSRAM) |
| MX (1) | MX346835B (OSRAM) |
| PE (2) | PE20141210A1 (OSRAM) |
| RU (1) | RU2625021C2 (OSRAM) |
| TW (2) | TWI623618B (OSRAM) |
| WO (1) | WO2013007772A1 (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| JP2015128397A (ja) * | 2014-01-08 | 2015-07-16 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法 |
| WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| JP6566368B2 (ja) * | 2015-04-16 | 2019-08-28 | 国立研究開発法人産業技術総合研究所 | B型肝炎ウイルス分泌阻害剤 |
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스 감염에 대한 rnai 치료법 |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| AU2017347725B2 (en) | 2016-10-17 | 2024-01-04 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
| EP4242298A2 (en) * | 2016-12-02 | 2023-09-13 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| JP7406377B2 (ja) | 2017-05-15 | 2023-12-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定なウイルス含有組成物 |
| US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| JOP20200153A1 (ar) * | 2017-12-19 | 2022-10-30 | Janssen Sciences Ireland Unlimited Co | لقاحات التهاب الكبد الفيروسي b (hbv) واستخداماته |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| SG11202005709QA (en) * | 2017-12-19 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
| JP7494117B2 (ja) | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
| AU2019231652B2 (en) * | 2018-03-06 | 2025-05-22 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| MX2020009262A (es) | 2018-03-07 | 2021-01-08 | Transgene | Vectores de parapoxvirus. |
| AU2019359204B2 (en) | 2018-10-08 | 2024-12-05 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
| US20220233684A1 (en) * | 2019-06-18 | 2022-07-28 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
| CA3141238A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
| WO2020255007A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| WO2020255011A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| US20220305107A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| WO2020255055A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| WO2020255063A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
| EP4458975A3 (en) * | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
| KR20220117627A (ko) * | 2021-02-17 | 2022-08-24 | 주식회사 녹십자 | 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물 |
| CN115851656A (zh) * | 2021-09-24 | 2023-03-28 | 中国科学院生物物理研究所 | 一种乙肝病毒聚合酶的制备方法 |
| CN116333170A (zh) * | 2023-03-28 | 2023-06-27 | 陇东学院 | 一种用于免疫治疗胃癌的重组病毒样纳米颗粒及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2650838A1 (fr) | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
| EP0534615B1 (en) | 1991-08-26 | 2001-01-03 | Epimmune Inc. | HLA-restricted hepatitis B virus CTL epitopes |
| DE69434954T2 (de) | 1993-02-26 | 2007-12-20 | The Scripps Research Institute, La Jolla | Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ATE227118T1 (de) * | 1993-08-02 | 2002-11-15 | Scripps Research Inst | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
| IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| AU732703B2 (en) | 1996-11-20 | 2001-04-26 | Crucell Holland B.V. | An improved method for the production and purification of adenoviral vectors |
| CA2274876A1 (en) | 1996-12-13 | 1998-06-18 | Schering Corporation | Method for purifying viruses |
| EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| PL373675A1 (en) * | 2001-02-05 | 2005-09-05 | Stressgen Biotechnologies Corporation | Hepatitis b virus treatment |
| ES2322043T3 (es) | 2001-06-22 | 2009-06-16 | The Wistar Institute Of Anatomy And Biology | Procedimientos de indusccion de una respuesta citotoxica inmune y composiciones de adenovirus de simio recombinante utiles en los mismos. |
| KR100987360B1 (ko) | 2001-11-21 | 2010-10-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| GB0328753D0 (en) | 2003-12-11 | 2004-01-14 | Royal Veterinary College The | Hepatitis B vaccines |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| CN100339488C (zh) * | 2004-12-07 | 2007-09-26 | 中山大学达安基因股份有限公司 | 乙型肝炎病毒基因组耐药突变检测方法 |
| CN1313483C (zh) * | 2005-12-12 | 2007-05-02 | 浙江大学 | 鸭乙型肝炎病毒多聚酶蛋白ymdd功能区的抑制肽及应用 |
| KR101141333B1 (ko) | 2006-06-20 | 2012-05-23 | 트랜스진 에스.에이. | 재조합 바이러스 백신 |
| CN101573449B (zh) | 2006-08-14 | 2013-09-18 | 浦项工大产学协力团 | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 |
| KR20080086687A (ko) | 2007-03-23 | 2008-09-26 | 주식회사 파나진 | 라미부딘 내성 b형 간염바이러스 검출을 위한 ρνα프로브, 키트 및 방법 |
| TW200844230A (en) | 2007-05-15 | 2008-11-16 | Transgene Sa | Signaling peptides |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| CN101688182A (zh) | 2007-07-03 | 2010-03-31 | 特兰斯吉恩股份有限公司 | 永生化禽细胞系 |
| EP2220217A2 (en) | 2007-11-28 | 2010-08-25 | The Trustees of the University of Pennsylvania | Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof |
| CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| CA2706257C (en) | 2007-11-28 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Simian subfamily b adenovirus sadv-28, -27, -29, -32, -33 and -35 and uses thereof |
| CN102016011B (zh) | 2008-03-04 | 2013-12-11 | 宾夕法尼亚大学托管会 | 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用 |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| KR20120026526A (ko) | 2009-05-12 | 2012-03-19 | 트랜스진 에스.에이. | 불멸화 조류 세포주 및 그의 용도 |
| WO2011001565A1 (ja) | 2009-07-01 | 2011-01-06 | シャープ株式会社 | 液晶表示素子及び液晶表示装置 |
| NZ598000A (en) * | 2009-08-07 | 2013-10-25 | Transgene Sa | Composition for treating hbv infection |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
-
2012
- 2012-07-11 TW TW105141433A patent/TWI623618B/zh active
- 2012-07-11 TW TW101124905A patent/TWI575070B/zh active
- 2012-07-12 EP EP12733748.3A patent/EP2732034B1/en active Active
- 2012-07-12 BR BR112014000627-0A patent/BR112014000627B1/pt not_active IP Right Cessation
- 2012-07-12 ES ES12733748.3T patent/ES2632497T3/es active Active
- 2012-07-12 RU RU2014104360A patent/RU2625021C2/ru active
- 2012-07-12 JP JP2014519553A patent/JP6189293B2/ja not_active Expired - Fee Related
- 2012-07-12 CN CN201280044383.1A patent/CN103998604B/zh active Active
- 2012-07-12 MX MX2014000488A patent/MX346835B/es active IP Right Grant
- 2012-07-12 AU AU2012282506A patent/AU2012282506C1/en not_active Ceased
- 2012-07-12 HU HUE12733748A patent/HUE033789T2/en unknown
- 2012-07-12 PE PE2014000055A patent/PE20141210A1/es active IP Right Grant
- 2012-07-12 PE PE2019000402A patent/PE20190660A1/es unknown
- 2012-07-12 KR KR1020147003482A patent/KR102061357B1/ko not_active Expired - Fee Related
- 2012-07-12 CA CA2841890A patent/CA2841890C/en active Active
- 2012-07-12 US US14/232,082 patent/US9512412B2/en not_active Expired - Fee Related
- 2012-07-12 DK DK12733748.3T patent/DK2732034T3/en active
- 2012-07-12 WO PCT/EP2012/063640 patent/WO2013007772A1/en not_active Ceased
-
2014
- 2014-01-12 IL IL230402A patent/IL230402B/en active IP Right Grant
-
2016
- 2016-12-05 US US15/369,118 patent/US10190105B2/en active Active
-
2019
- 2019-01-25 US US16/257,784 patent/US10662414B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527404A5 (OSRAM) | ||
| US10662414B2 (en) | Methods for treating or preventing HBV infection or HBV related diseases | |
| JP2013501038A5 (OSRAM) | ||
| CN103442732B (zh) | 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗 | |
| JP7317017B2 (ja) | B型肝炎ウイルス(hbv)ワクチンおよびその使用 | |
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
| JP2021506300A (ja) | B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物 | |
| CN101717433A (zh) | 一种多肽免疫原及其制备方法和应用 | |
| CN115335075A (zh) | 治疗和预防乙型肝炎和丁型肝炎的组合物和方法 | |
| HK1192456B (en) | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same | |
| HK1192456A (en) | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |